High-Intensity Interval Training Versus Moderate-Intensity Continuous Training in Physically Trained Adults
NCT07915349, Not applicable, Completed, Agri Ibrahim Cecen University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | High-Intensity Interval Training Versus Moderate-Intensity Continuous Training in Physically Trained Adults | ClinicalTrials.gov |
| NCT number | NCT07915349 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 46 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Agri Ibrahim Cecen University | ClinicalTrials.gov |
| Conditions | Physical Fitness, Cardiorespiratory Fitness | ClinicalTrials.gov |
| Interventions | High-Intensity Interval Training, Moderate-Intensity Continuous Training | ClinicalTrials.gov |
| First posted | 2026-11-04 | ClinicalTrials.gov |
| Last updated | 2026-11-04 | ClinicalTrials.gov |
Registered outcomes 21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change from Baseline in Estimated Maximal Oxygen Uptake (VO2max) | Baseline, Week 4, and Week 8 | Estimated VO2max was determined using an incremental cycle-ergometer test and the FRIEND equation based on peak work rate and body mass. Values were expressed in mL/kg/min. Changes from baseline were assessed at weeks 4 and 8. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Wingate Peak Power | Baseline, Week 4, and Week 8 | Peak anaerobic power was assessed during the 30-second Wingate cycle-ergometer test. The highest power output during a 5-second interval was recorded and normalized to body mass (W/kg). | ClinicalTrials.gov |
| Secondary | Change from Baseline in Wingate Mean Power | Baseline, Week 4, and Week 8 | Mean anaerobic power was assessed during the 30-second Wingate cycle-ergometer test. Average power output was normalized to body mass and expressed in W/kg. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Wingate Fatigue Index | Baseline, Week 4, and Week 8 | The fatigue index was calculated during the 30-second Wingate test as the percentage decline from peak to minimum power output. Values were expressed as percentages (%). | ClinicalTrials.gov |
| Secondary | Change from Baseline in Wingate Total Work | Baseline, Week 4, and Week 8 | Total mechanical work performed during the 30-second Wingate cycle-ergometer test was normalized to body mass and expressed in J/kg. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Single-Leg Stance Duration | Baseline, Week 4, and Week 8 | Static postural balance was assessed by measuring the duration participants maintained a single-leg stance on a firm surface. Performance was expressed in seconds. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Balance Error Scoring System (BESS) Total Score | Baseline, Week 4, and Week 8 | Postural stability was assessed using the Balance Error Scoring System across six standing conditions on firm and foam surfaces. The total number of balance errors was recorded, with lower scores indicating better postural control. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Y-Balance Test Composite Score | Baseline, Week 4, and Week 8 | Dynamic balance was assessed using the Y-Balance Test in anterior, posteromedial, and posterolateral directions. Reach distances were normalized to lower-limb length and expressed as a composite percentage score (%). | ClinicalTrials.gov |
| Secondary | Change from Baseline in Timed Up and Go Test Performance | Baseline, Week 4, and Week 8 | Functional mobility was evaluated using the Timed Up and Go test. Participants stood from a chair, walked 3 meters, turned, returned, and sat down. Completion time was recorded in seconds, with shorter times indicating better performance. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Forced Vital Capacity (FVC) | Baseline, Week 4, and Week 8 | Forced vital capacity (FVC) was measured by spirometry using the COSMED MicroQuark system and expressed in liters (L). The change from baseline was assessed at weeks 4 and 8. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Forced Expiratory Volume in One Second (FEV1) | Baseline, Week 4, and Week 8 | Forced expiratory volume in one second (FEV1) was measured using the COSMED MicroQuark spirometer and expressed in liters (L). The change from baseline was assessed at weeks 4 and 8. | ClinicalTrials.gov |
| Secondary | Change from Baseline in FEV1/FVC Ratio | Baseline, Week 4, and Week 8 | The ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) was calculated and expressed as a percentage (%). The change from baseline was assessed at weeks 4 and 8. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Forced Mid-Expiratory Flow (FEF25-75) | Baseline, Week 4, and Week 8 | Forced mid-expiratory flow between 25% and 75% of forced vital capacity (FEF25-75) was measured using the COSMED MicroQuark spirometer and expressed in liters per second (L/s). The change from baseline was assessed at weeks 4 and 8. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Peak Expiratory Flow (PEF) | Baseline, Week 4, and Week 8 | Peak expiratory flow (PEF) was measured during forced expiration using the COSMED MicroQuark spirometer and expressed in liters per second (L/s). The change from baseline was assessed at weeks 4 and 8. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Maximal Voluntary Ventilation (MVV) | Baseline, Week 4, and Week 8 | Maximal voluntary ventilation (MVV) was measured using the COSMED MicroQuark spirometry system and expressed in liters per minute (L/min). The change from baseline was assessed at weeks 4 and 8. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Natural Log-Transformed RMSSD (lnRMSSD) | Baseline, Week 4, and Week 8 | The natural log-transformed root mean square of successive differences between normal heartbeats (lnRMSSD) was derived from resting cardiac interbeat intervals recorded using a Polar H10 chest strap and analyzed with Kubios HRV Premium software. Values were expressed on the natural-log scale (ln\[ms\]). The change from baseline was assessed at weeks 4 and 8. | ClinicalTrials.gov |
| Secondary | Change from Baseline in SDNN | Baseline, Week 4, and Week 8 | The standard deviation of normal-to-normal heart-beat intervals (SDNN) was calculated from resting cardiac interbeat interval recordings acquired using a Polar H10 chest strap and analyzed with Kubios HRV Premium software. Values were expressed in milliseconds (ms). The change from baseline was assessed at weeks 4 and 8. | ClinicalTrials.gov |
| Secondary | Change from Baseline in LF/HF Power Ratio | Baseline, Week 4, and Week 8 | The ratio of low-frequency to high-frequency heart rate variability power (LF/HF) was derived from resting recordings using a Polar H10 chest strap and Kubios HRV Premium software. Values were expressed as a unitless ratio. The change from baseline was assessed at weeks 4 and 8. | ClinicalTrials.gov |
| Secondary | Change from Baseline in High-Frequency HRV Power (HF) | Baseline, Week 4, and Week 8 | High-frequency (HF) heart rate variability power was derived from resting recordings using a Polar H10 chest strap and Kubios HRV Premium software. Values were expressed in milliseconds squared (ms²). The change from baseline was assessed at weeks 4 and 8. | ClinicalTrials.gov |
| Other | Change from Baseline in Dominant-Hand Grip Strength | Baseline, Week 4, and Week 8 | Maximum voluntary grip strength of the dominant hand was measured using a hand dynamometer and expressed in kilogram-force (kgf). The change from baseline was assessed at weeks 4 and 8. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)